Leerink raises Elevance stock price target on stable cost trends By Investing.com

Leerink Partners raised its price target on Elevance Health to $364 from $357 while keeping a Market Perform rating, citing stable cost trends and slight Medicare Advantage outperformance after Q1 2026 results. Elevance reported adjusted diluted EPS of $12.58 versus $10.84 expected and revenue of $49.5 billion versus $48.2 billion expected, while Barclays and Evercore ISI also lifted targets to $408 and $360, respectively. Medicaid remains a cautious area, but commercial and Medicaid membership beat expectations and the company reiterated its 2026 Medicaid margin outlook of -1.75%.

Analysis

ELV’s setup is less about this quarter’s beat and more about the market gradually re-rating the durability of its managed-care earnings power. The key second-order effect is that a stable cost trend and better Medicare Advantage execution reduce the probability of a near-term multiple compression event, which matters more than the modest PT changes themselves. That said, the stock is now closer to fair value than “deeply undervalued,” so incremental upside likely depends on whether Medicaid inflection shows up sooner than consensus expects.

The market is still underappreciating how much of the near-term narrative can be driven by mix rather than absolute claims. If commercial and Medicare stay constructive while Medicaid remains merely stable, ELV can keep compounding even without a dramatic underwriting reset. The risk is that investors extrapolate one clean quarter into a multi-quarter trend; Medicaid tends to disappoint at the margin when utilization and redeterminations leak through with a lag of 1-2 quarters.

Catalyst-wise, the next 30-60 days matter most: commercial selling season commentary and any follow-through on margin cadence will determine whether this is a trading bounce or a more durable re-rating. A reversal would likely come from either a step-up in medical cost trend or evidence that the 2026 guide still embeds too much help from one-time items. In contrast, if cost discipline persists into the next print, ELV can continue to grind higher even without a full-throated thesis upgrade.

The contrarian read is that the market may be too focused on the headline beat and not enough on the asymmetry between what’s improving now versus what can still deteriorate later. ELV is probably not a momentum name from here; it is a quality compounder with limited multiple expansion unless Medicaid fears fade. In other words, upside is more likely to come from earnings revisions than sentiment, and that usually takes a few quarters, not a few days.

Key Decisions for Investors

• Hold a tactical long in ELV for the next 2-6 weeks only if you can tolerate mean reversion; target a move toward the low-$360s on continued analyst flow, with a stop if managed-care names roll over on any cost-trend scare.
• Use ELV as a relative-value long against weaker Medicaid-exposed managed care names over 1-3 months; the cleaner execution profile gives ELV better downside protection if the sector de-rates.
• Sell upside via covered calls or call spreads in ELV rather than chasing outright equity here; implied upside is now more dependent on revisions than multiple expansion, which caps near-term convexity.
• If you want exposure to healthcare defensiveness, rotate into ELV only on pullbacks below current levels; above the mid-$340s, risk/reward shifts from attractive to fairly balanced.
• Set a catalyst alert around the next commentary on Medicaid trend and commercial selling season; if either disappoints, expect the stock to give back most of the post-earnings multiple expansion within days rather than months.